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ABSTRACT
Antiviral Activity of Favipiravir (T-705) Against Lethal Rift Valley Fever Virus Infection in
Hamsters
by
Dionna Scharton, Master of Science
Utah State University, 2014
Major Professor: Brian B. Gowen
Department: Animal, Dairy and Veterinary Science

Rift Valley Fever is a zoonotic, arthropod-borne disease that adversely affects ungulates
and people. The etiologic agent, Rift Valley fever virus (RVFV; Bunyaviridae, Phlebovirus), is
primarily transmitted through mosquito bites, yet can be transmitted by exposure to infectious
aerosols. Presently, there are no licensed vaccines or therapeutics to prevent or treat severe
RVFV infection in humans. We have previously reported on the activity of favipiravir (T-705)
against the MP-12 vaccine strain of RVFV and other bunyaviruses in cell culture. Additionally,
efficacy has been documented in mouse and hamster models of infection with the related
Punta Toro virus. Here, we characterize a hamster RVFV challenge model and use it to evaluate
the activity of favipiravir against the highly pathogenic ZH501 strain of the virus. Subcutaneous
RVFV challenge resulted in substantial serum and tissue viral loads and caused severe disease
and mortality within 2-3 days after infection. Oral favipiravir (200 mg/kg/day) prevented
mortality in 60% or greater in hamsters challenged with RVFV when administered within 6 h
post-exposure and reduced RVFV titers in serum and tissues relative to the time of treatment
initiation. In contrast, although ribavirin (75 mg/kg/day) was effective at protecting animals
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from the peracute RVFV disease, most ultimately succumbed from a delayed-onset neurologic
disease associated with high RVFV burden in the brain observed in moribund animals. When
combined, T-705 and ribavirin treatment started 24 h post-infection significantly improved
survival outcome and reduced serum and tissue virus titers compared to monotherapy. Our
findings demonstrate significant post-RVFV exposure efficacy with favipiravir against both
peracute disease and delayed-onset neuroinvasion, and suggest added benefit when combined
with ribavirin.
(74 pages)
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PUBLIC ABSTRACT
Efficacy of Favipiravir (T-705) Against Lethal Rift Valley Fever Virus Infection in Hamsters
Dionna Scharton
Rift Valley fever (RVF) is a severe disease affecting both humans and a number of
agriculturally important livestock species. The causative agent, RVF virus (RVFV), is primarily
transmitted through mosquito bites, with transmission also occurring by exposure to infectious
aerosols and direct contact with infected body fluids such as blood. Presently, there are no
licensed vaccines or medicines to prevent or treat severe RVFV infection in humans. Favipiravir
(T-705) is a novel compound licensed for the treatment of influenza in Japan and presently in
Phase III clinical trials in the US, which has demonstrated favorable activity against an
attenuated strain of RVFV, as well as other related viruses in cell culture. Additionally, it has also
demonstrated favorable activity in mouse and hamster models based on infection with the
closely related, less biohazardous Punta Toro virus. Although mouse models have been used
extensively in RVFV research and are fairly well characterized, details regarding RVFV infection
in hamsters are lacking. The present studies were aimed at characterizing RVFV infection in
hamsters to gain a better understanding of the disease model compared to human disease, and
employing the hamster infection model to evaluate T-705 as a promising broadly active antiviral
with potential for off-label use to treat severe RVF disease. Herein, we describe the natural
history of disease in hamsters challenged with low infectious doses of RVFV and demonstrate
the efficacy of T-705 in preventing mortality and reducing viral loads in infected hamsters. Our
results support the future use of the RVFV hamster infection model for early stage antiviral drug
and vaccine development studies, as well as further development of T-705 using more advanced
nonhuman primate models of disease.
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CHAPTER 1
INTRODUCTION - LITERATURE REVIEW
RIFT VALLEY FEVER VIRUS AND FAVIPIRAVIR
Introduction
Rift Valley fever (RVF) is a zoonotic infectious disease responsible for multiple epidemics
and epizootics throughout Africa and the Arabian Peninsula. The etiologic agent, RVF virus
(RVFV; Bunyaviridae, Phlebovirus) is principally transmitted by mosquitoes and typically
manifests as an acute, self-limiting febrile illness; however, infection can lead to severe disease
characterized by hemorrhagic fever, hepatitis, retinitis, and occasionally late-onset encephalitis
[1-3]. Case-fatality rates in hospitalized patients are estimated to be 20%. Many ungulates are
highly susceptible to RVFV infection. Mortality among young animals is especially high and
gestating animals often experience spontaneous abortions. Outbreaks have had devastating
effects on public and veterinary health, animal agriculture and both regional and national
economies. Recent RVF outbreaks affecting both humans and ruminants have occurred in
Mauritania (2012), South Africa (2010), Madagascar (2008), Sudan (2007-2008), Kenya (20062007), Somalia (2007), Tanzania (2007), Yemen (2000), and Saudi Arabia (2000) underscore the
importance of this neglected tropical disease [4].
Molecular Biology of RVFV
RVFV is a spherical, enveloped virus containing a negative-sense RNA genome that is
divided into three segments: small (S), medium (M) and large (L). The S segment encodes in an
ambisense manner the nucleocapsid protein (N), which encapsidates the viral genome and a
nonstructural protein, NSs, which is involved in the inhibition of the host innate-immune
response [2,5,6]. The M segment encodes two envelope glycoproteins, Gn and Gc, and a
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nonstructural protein, NSm; the L segment encodes an RNA-dependent RNA-polymerase (RdRp).
Virions enter a host organism via direct contact with infected fluids/tissues or inhalation of
aerosolized infectious particulate. RVFV is thought to gain entry into host cells by endocytosis
and fusion with the plasma membrane is induced by a low pH [7,8]. Transcription and
replication occur in the cytoplasm of host cells and require both RdRp and N, while Gn and Gc
enter the secretory system [6,9]. The envelope glycoproteins form a complex which localizes in
steady-state to the Golgi apparatus for virion maturation [10,11]. The assembled virus
subsequently buds into the lumen of the Golgi apparatus, gets transported to, and then fuses
with the plasma membrane, allowing virions to be released from the cell into the extracellular
matrix [9-11] where they can gain access to neighboring uninfected cells and begin the
replication process once again.
Light microscopy, electron microscopy, quantitative real-time PCR, in vivo and ex vivo
imaging studies of RVFV infection and replication demonstrate a large tropism for a variety of
tissues and cell types. Upon infection, it is presumed the virus replicates at the exposure site
and the draining lymphatics; subsequent viremia seeds the target organs. During this stage of
the infection, viral replication mainly targets the liver (particularly hepatocytes), spleen, thymus,
brain and pancreas [12-14]. Utilization of a fluorescence-activated cell sorting analysis in
recombinant GFP-expressing RVFV-infected mice demonstrated macrophages, dendritic cells
and granulocytes to be the main target cells for RVFV replication [12]. Viral antigens have been
detected in lymph node macrophages, and mononuclear phagocytic cells and dendritic cells in
the spleen, thymus and lymph nodes of rats and mice [12-14].
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RVFV Transmission
RVF outbreaks generally follow periods of heavy rainfall and flooding, which create an
ideal breeding environment for mosquito vectors [15-18]. The virus is typically spread by a
variety of mosquito species, mainly those in the Aedes and Culex genera, although sandflies and
certain midge and tick species have also been identified as vectors [16]. Various Aedes
subspecies have been identified as the primary vector for RVFV. Of particular note, Aedes
mcintoshi also has the ability to transmit the virus transovarially; RVFV persists in the infected
mosquito eggs between epizootic periods, possibly representing the viral reservoir [19]. The
cycle continues when the infected larvae hatch during periods of heavy rainfall emerging and
feeding on nearby animals [20]. Amplification occurs mainly with Culex and other subspecies of
mosquitos, which feed on the newly-infected animals and propagating the infection cycle
through feeding on naïve animals. Other studies have demonstrated the capability of RVFV to
be preserved in an enzootic cycle involving both Aedes and Culex mosquitos [16,18,21,22].
Transmission of the virus also occurs through direct contact with infected body fluids
and tissues, and by aerosol transmission [23-26]. Past reports have documented the
transmission of RVFV to slaughterhouse workers, animal handlers (including veterinary
students) and laboratory staff which have come into contact with infected specimens/samples
[15,26].
RVFV’s Increasing Geographic Distribution
In July 1930, farmers from the Great Rift Valley in Kenya reported gestating ewes
spontaneously aborting and high mortality in newly-born lambs which prompted investigation
and the subsequent identification of RVFV [26]. Since its discovery, the geographic distribution
of RVFV has spread from this endemic region to neighboring countries, including Egypt,
Madagascar, and regions in western Africa. The identification of RVFV in the Arabian Peninsula

4
in 2000 was the first RVFV epidemic recognized outside the continent of Africa [24,27-29].
These severe outbreaks have involved hundreds of thousands of people and animals and have
caused substantial economic losses, particularly within livestock production [24,27,29].
A recent study published the genome sequence of 33 different strains of RVFV from past
outbreaks throughout Africa and Saudi Arabia [17]. Phylogenic analysis of these samples
suggests the emergence of the originating strain of today’s RVFV occurred in the late 1800’s.
Coincidentally, this was also when an agricultural shift was occurring, where indigenous
livestock populations were becoming replaced by imported European breeds. It is speculated
that the imported cattle and sheep, being highly susceptible to RVFV, were instrumental in
endemic RVFV establishment; subsequent movement of these infected animals/herds and
mosquitoes would conceivably propagate the dissemination of the virus throughout naïve
regions [17]. Accordingly, should the virus be introduced, widespread transmission could readily
occur in the United States and other Western countries where the vector species are endemic
and susceptible hosts are present [6,30,31].
Clinical Pathology of RVF
RVF epizootics are usually marked by an unexplained sudden onset of abortions in
pregnant animals and high mortality rates in neonates following seasonal heavy rains; human
RVF epidemics generally arise during these epizootic episodes [32-34]. Susceptibility of
ruminant animals to RVFV infection varies greatly depending on a host of factors such as the
viral strain and the species and age of the infected animal [2,5]. Typically, RVF manifests with
the sudden onset of abortions (“abortion storms”) in the majority of pregnant animals within a
herd, coupled with a high incidence of mortality in the young. Young sheep, particularly lambs
(≤ 1 week old), appear to be the most susceptible to RVFV infection, with incidents of mortality
reaching 90 – 100%; mortality of adult sheep in experimental RVFV infection is approximately
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20% [35]. Goats display similar degrees of illness and mortality to that of sheep, whereas cattle
experience comparable clinical symptoms, but mortality rates in adult animals are much lower
(<10%) [35]. Infected animals clinically demonstrate a biphasic febrile reaction with severe
prostration and collapse in young animals, agalactia in milk-producing females, nasal and (in
cattle) lachrymal discharge, lymphadenitis, hemorrhagic diarrhea, debility with jaundice and
death in older animals [1,26,36].
The clinical pathology of RVF is usually marked by leukopenia, high levels of enzymes
associated with liver damage (i.e. alanine aminotransferase [ALT], glutamate dehydrogenase
[GLDH]) and thrombocytopenia [26,36]. Postmortem investigation of RVFV-infected animals
find that the liver is the primary site of pathological change where hepatic lesions progress to a
massive necrotic hepatitis [26,36]. Extensive hemorrhaging (petechial and ecchymotic
hemorrhages and hemorrhagic gastroenteritis), generalized lymphadenopathy and pulmonary
edema and emphysema have been identified as postmortem indications [36].
In people, the virus has an incubation period of 2-6 days, after which flu-like symptoms
appear and typically last 2-7 days after onset of illness. Symptoms are generally described as an
abrupt onset of fever, chills, and lethargy with 1-3% of cases progressing to more serious forms
of the disease including hemorrhagic syndrome, acute-onset hepatitis, delayed-onset
encephalitis with long-term neurologic deficits, and retinal vasculitis and macular lesions that
can result in varying degrees of blindness [32,33]. In severe cases of RVF, the fatality rate is 1020%, but in recent outbreaks it has climbed as high as 40% [29].
RVFV Infection Animal Models
Mouse models of RVFV infection are the most widely used for antiviral research and
pathogenesis studies due to their susceptibility, similar disease pathology to newborn lambs and
humans, and relatively low cost [2,37,38]. Typically, mice infected with the ZH501 strain die
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within 3 to 7 days [13,39-41]. Clinical signs become apparent within 2 to 3 days post-infection
(p.i.) indicated by ruffled fur, hunched posture and lethargy. Mice generally succumb from
acute hepatitis or delayed meningoencephalitis. Although RVFV demonstrates diverse tissue
tropism, as evidenced by high viral loads in a variety of tissues, histologic and
immunohistochemical (IHC) examination of these tissues reveal the liver is the principle target
organ. An overwhelming infection of hepatocytes results in cell damage, thereby elevating
serum ALT and bilirubin levels, and frequently resulting in death by day 3 p.i. [2,38].
Interestingly, mice which survive the acute hepatic phase generally succumb to a late
developing encephalitis, similar to that seen in human RVFV infection [13]. Additional histologic
findings include congestion and hemorrhage of the liver, brain, spleen, lymph nodes, large
intestine and the kidneys [2].
RVFV infection by both sub-cutaneous (s.c.) and aerosol routes in different strains of
inbred rats reveals marked differences in susceptibility, disease progression and lethality.
Following parenteral infection, Fisher 344, Buffalo, DA and Lewis strains of rats are essentially
resistant to RVFV infection, ACI and Maax strains are moderately susceptible and Wistar-Furth
and Brown Norway strains are highly susceptible [2,42,43]. When challenged by s.c. route, the
Wistar-Furth and Brown Norway animals succumb to a fulminant hepatitis characterized by
severe hepatocellular necrosis. To a lesser extent, necrotic lesions were also detected in the
spleen, particularly the red pulp. Additionally, viremia and high viral loads in a variety of tissues,
including the liver, spleen, lungs and kidneys have been reported; these pathogenic
characteristics are similar to those reported in RVFV infected mice. In contrast, virus was not
detected in the liver or blood of ACI and Maax strains; these animals succumbed to encephalitis.
Aerosol challenge demonstrated that Wistar-Furth rats were the only strain to develop and
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succumb to acute hepatic disease, whereas the ACI and Lewis rat strains both developed fatal
encephalitis.
With death occurring 2 – 3 days post-RVFV infection, golden Syrian hamsters are one of
the most susceptible rodent species [44-46]. Despite being one of the first laboratory animals to
be challenged with the virus [26], very little work has been done characterizing the pathogenesis
of RVFV infection in hamsters. Similar to mice, pathological changes to the liver involve an
overwhelming infection of hepatocytes [37]. In a subsequent study, the hamster model was
used to determine a minimum protective titer after passive and active immunization [44].
Immunized animals had a high variation in antibody response, more than any other tested
rodents. Additionally, it was discovered that the passive administration of low titers of
neutralizing antibodies protected animals from fulminant hepatitis, yet animals ultimately
succumbed from delayed-onset encephalitis. As this study was aimed towards comparison of
active and passive immunization, further investigations towards understanding the
pathogenesis of encephalitis was not conducted [44].
The gerbil represents a distinctive RVFV infection model, typically succumbing to fatal
encephalitis in the absence of extraneural lesions and with minimal liver involvement, in
contrast to other rodent systems [47]. Moderately susceptible to RVFV infection, animals
typically die within 1 to 3 weeks in an infectious dose-dependent manner. Remarkably, animals
also exhibited age-dependent resistance to RVFV infection, where viral replication in the brain
occurred in 4-week-old gerbils, but not in 10-week-old gerbils. Histologic examination of the
brain revealed a focal necrotizing encephalitis with neuronal necrosis [47].
Recently, two distinct novel non-human primate (NHP) RVFV infection models utilizing
marmosets and African Green monkeys (AGMs) were published. As RVFV infection in the rhesus
macaque NHP model is not uniformly lethal and variations in susceptibility when using different
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strains of RVFV have been reported [38,48], the marmoset and AGM were evaluated as possible
alternatives [49,50]. Regardless of the exposure route (s.c., i.v. and i.n.), marmosets were found
to be more susceptible to infection than the rhesus macaque, as these animals quickly
succumbed to a lethal hepatitis, characterized by robust infection of hepatocytes. Additionally,
signs of viral hemorrhagic fever (VHF), neurologic impairment and possible retinitis were
observed [49]. When both marmosets and AGMs were infected via aerosol challenge,
marmosets were found to be more susceptible to lower doses of RVFV than AGM (3.5 x 103 PFU
vs. 1.17 x 105 PFU, respectively). Despite this, clinical signs of encephalitis and mortality rates
between the two species were comparable to each other and the data suggests that both AGMs
and marmosets would be suitable disease models for human RVFV aerosol exposure [43].
Furthermore, the ability of marmosets to reproduce lethal hepatitis and encephalitis can serve
as a useful model towards evaluating promising antiviral compounds and vaccines.
Vaccine and Therapeutic Development
Currently, two vaccines are approved for the prophylactic immunization of livestock.
The Smithburn vaccine is a live attenuated vaccine, and although useful in rapidly providing
long-term immunity after a single dose, its use has led to high abortion rates and/or teratology
in a significant number of gestating animals [51-53]. The second vaccine is a formalin
inactivated aluminum hydroxide-adjuvant vaccine based on a low passage wild-type RVFV strain.
This type of vaccine is costly to produce and requires multiple inoculations with regular
boosters, but is useful during outbreaks, particularly in non-endemic areas [54,55].
The only RVFV vaccine currently available for human use is TSI-GSD-200. Derived from
the RVFV vaccine NDBR-103 to reduce inter-lot variation, TSI-GSD-200 is a formalin-inactivated
vaccine that is available to personnel working in high infectious risk and/or endemic areas.
Unfortunately, the vaccine is costly and difficult to produce, requires a large dose volume
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(relative to an attenuated vaccine), three initial inoculations, a 6-month booster and continual
annual boosters [55-57]. A promising live-attenuated vaccine, MP-12, was generated via
mutagenesis of an RVFV strain (ZH548) isolated from the 1977 outbreak in Egypt and grown in
MRC-5 human diploid fibroblast cells [58,59]. The MP-12 vaccine has demonstrated efficacy in
multiple livestock studies [60-62] and, more recently, it was evaluated in Phase II clinical trials
with favorable results with confirmatory reports still pending [55,63].
While vaccines are the primary defense against viral diseases [64] the need for the
development of effective antiviral therapeutics is another essential component towards fighting
severe viral infections [65]. The antiviral compound ribavirin is the only licensed drug that can
be used for emergency treatment of RVFV infection. Acting as a purine nucleoside analog,
ribavirin is a broad spectrum antiviral for which the principle mechanism of action in vivo
remains undetermined. Evidence reported in previous studies indicate direct (polymerase
inhibition, RNA capping interference and lethal mutagenesis) and indirect (inosine
monophosphate dehydrogenase inhibition and immunomodulatory effects) mechanisms may
both play important roles in ribavirin’s antiviral activity [66,67]. Unfortunately, due to adverse
side effects such as dose-related hemolytic anemia and teratogenic effects, ribavirin is only
approved for compassionate use under investigational new drug protocols for the treatment of
RVF, several other bunyaviral hemorrhagic fevers, and hemorrhagic fever of arenaviral origin
[68,69]. Additionally, the use of emergency ribavirin therapy as the post-exposure treatment of
RVFV exposure has been reported to have unforeseen negative consequences. During the Saudi
Arabia outbreak, ribavirin was used to treat patients suffering from hemorrhagic manifestation
associated with RVFV infection. Despite apparent success in resolving the hemorrhagic
symptoms, patients later succumbed to a severe late-onset of meningoencephaltic
complications [55]. The ribavirin molecule is too large to effectively bypass the blood-brain
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barrier (BBB), therefore the development of safer and more effective antivirals that can gain
access to the central nervous system are needed [55].
Another promising antiviral compound is favipiravir (6-flouro-3-hydroxy-2pyrazinecarboxamine), also called T-705, which is a pyrazine derivative that is an RdRp inhibitor
of the influenza virus and has demonstrated potent antiviral activity against multiple RNA
viruses [70]. Evidence suggests host cell enzymes convert T-705 into T-705-4-ribofuranosyl-5triphosphate (T-705RTP), the active form of the drug that selectively inhibits the viral
polymerase without affecting host cellular DNA or RNA synthesis [71]; this specificity is what
likely contributes to its low toxicity.
T-705 has demonstrated robust activity against the MP-12 vaccine strain of RVFV in cell
culture along with several other related bunyaviruses, including: several hantaviruses, La Crosse
virus, and Punta Toro and sandfly fever phleboviruses [40,72-74]. Punta Toro virus (PTV), a
more accessible and less biohazardous agent (biosafety level 2; BSL-2) belonging to the same
genus as RVFV, has been used to model severe RVFV infection in mice and hamsters [75-77].
Initial studies evaluating the efficacy of T-705 in the PTV infection models have yielded favorable
results, demonstrating a drastic reduction in mortality, viral loads in the tissues and sera and
liver disease [40,74].
Bioterrorism
RVFV is categorized as a potential biological weapon due to its transmissibility by
aerosol, ease of propagation in cell culture systems to very high titers, and its potential to be
modified by reverse genetics technologies into a more virulent agent which could escape
detection and/or prevention and control measures currently in development [32,78]. In
addition to the above, the threat RVFV poses to public health and animal agriculture and the
current lack of prophylactic countermeasures has resulted in the virus being classified as a
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priority Category A pathogen by the National Institute of Allergy and Infectious Diseases (NIAID)
and an overlap “Select Agent" by the Center for Disease Control (CDC) and the United States
Department of Agriculture (USDA) [78-81]. Because RVFV can quickly gain footholds in naïve
populations where competent vectors are abundant, the potential for expansion into other
continents such as North America and Europe is feasible [82,83]. The vulnerability of these
regions could result in worldwide spread and significant outbreaks of disease, further
emphasizing the need to develop safe and efficacious vaccine or post-exposure therapeutic.
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CHAPTER 2
MODEL DEVELOPMENT

Introduction
Rift Valley fever (RVF) is a zoonotic, arthropod-borne illness that typically manifests as
an acute febrile and hepatic disease in ungulates and humans. RVF is of notable public health
importance due to its severity, recurrent outbreaks and progressive geographic distribution
[6,10,17]. The etiological agent, Rift Valley fever virus (RVFV), is a member of the Bunyaviridae
family and the genus Phlebovirus. The virus has a tripartite single-stranded RNA genome which
encodes 7 proteins using an ambisense coding strategy [6,32]. It can be transmitted by a variety
of mosquito species, but is also spread via contact with infected fluids and tissues [26].
Susceptibility of livestock to RVFV infection varies greatly depending on the viral strain,
and the species and age of the infected animal [5]. Hepatic necrosis, an increase in liver
enzymes, and high viremia are characteristic of severe acute lethal infection in ruminants. In
humans, the virus has an incubation period of 2-6 days, after which flu-like clinical signs appear
and typically last 2-7 days after onset of illness [26,32,33]. Symptoms are generally described as
an abrupt onset of fever, chills, and lethargy with 1-3% of cases progressing to more serious
forms of disease including hemorrhagic syndrome, acute-onset hepatitis, delayed-onset
encephalitis with long-term neurologic deficits, and retinal vasculitis and macular lesions which
can result in varying degrees of blindness [2]. In severe cases of RVF, the fatality rate is 10-20%,
but in recent outbreaks it has climbed as high as 40% [29]. Currently, no FDA approved vaccines
or antiviral therapies for the prevention or treatment of RVF exist. Consequently, the
development of animal models to better understand the disease is of increasing importance
when considering the threat RVFV presents to public and animal health and the potential for
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importation into the US or other naïve regions of the world that harbor competent mosquito
vector populations [21,30,31].
The key pathological features of RVFV infection vary widely among animal species and
humans. Typically, RVFV infection that results in severe disease is characterized by
hepatocellular necrosis [26,84]. Because of the greater biohazard risk and “Select Agent” status
of RVFV, a surrogate hamster model for RVF is based on challenge with the related Punta Toro
virus (PTV), a BSL-2 agent, has been used for pathogenesis and antiviral studies [3]. Although
the hamster PTV infection model has proved useful for reproducing certain features of severe
human and animal RVFV infections where hepatic disease is a prominent pathological feature,
the animals fail to develop encephalitis [75,76]. Recently, a detailed characterization describing
the pathogenesis of RVFV infection in BALB/c mice reported hepatitis and encephalitis
consistent with severe human RVFV infection [13]. Additionally, a study using three different
inbred strains of rats infected with RVFV by both aerosol and sub-cutaneous (s.c.) routes
demonstrated remarkable differences in disease progression and lethality [42]. Wistar-Furth
rats were the only strain to develop and succumb to acute hepatic disease following aerosol
exposure. ACI and Lewis rat strains both developed fatal encephalitis after aerosol challenge,
but with varying degrees of susceptibility to RVFV; remarkably, Lewis rats are refractory to s.c.
challenge [42]. These differences are consistent with the varying clinical disease presentations
observed in humans. Although these murine and rat RVFV models are useful systems to
evaluate most vaccine and antiviral drug candidates, certain therapeutic platforms, particularly
those directed at host targets, may have little to no activity in mice or rats. For example,
consensus IFN, an FDA-licensed recombinant protein therapeutic, was evaluated in the hamster
PTV model because it does not cross-react with the mouse system [85,86].
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Hamsters models are becoming more widely used in infectious disease research with
greatest increase in use in the field of virology [87]. We recently evaluated a promising broadspectrum antiviral drug candidate and adenovirus vectored human consensus IFN in a model of
RVFV infection in hamsters [84,88]. Limited details describing RVFV infection and disease in
hamsters have previously been reported [37,44,45,89-91]. Here, we present linked virologic,
liver enzyme, and pathology findings during the course of RVFV infection in golden Syrian
hamsters challenged s.c. with the pathogenic ZH501 strain of RVFV to gain insights into the
natural history of disease in this small animal model of RVFV.
Materials and Methods
Virus and cells
The molecular clone of RVFV, strain ZH501, was obtained from Dr. Stuart Nichol (CDC,
Atlanta, GA). The virus stock (1.1 × 108 plaque-forming units (PFU/ml); 1 passage in BSRT7 cells,
3 passages in Vero E6 cells) used was from a clarified cell culture lysate preparation and was
inoculated by subcutaneous (s.c.) injection (ventral, right side of abdomen). The African green
monkey kidney cell line, Vero 76, was purchased from the American Type Culture Collection
(ATCC) (Manassas, VA) and maintained in minimal essential medium (MEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS) (GE Healthcare HyClone Laboratories, Logan, UT).
Animals and ethics regulation
Female 90-115 g golden Syrian hamsters (The Charles River Laboratory, Willimantic, CT)
were quarantined for 7 days prior to challenge and fed standard Harlan lab block and tap water
ad libitum. All animal procedures complied with USDA guidelines and were conducted at the
AAALAC-accredited Laboratory Animal Research Center at Utah State University under protocol
2011, approved by the Utah State University Animal Care and Use Committee.
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Titration of RVFV in hamsters
To determine the most appropriate RVFV challenge dose for the natural history study,
hamsters (n=5-6/group) were challenged by s.c. injection with a 0.2 ml inoculum containing
varying log 10 dilutions of RVFV spanning 6 orders of magnitude. The s.c. challenge was intended
to simulate natural mosquito-borne transmission. The animals were observed 15 days for
morbidity and mortality, and weighed every 3 days starting on the day of challenge.
Natural history of RVFV infection in hamsters
Based on the titration study, challenge doses of 10 PFU or 1 PFU were selected to
evaluate the progression and tissue tropism of RVFV infection. Hamsters (n=4-6/group) were
selected for sacrifice on days 1 through 4 post s.c. challenge with RVFV. Various tissue samples
were collected (pancreas, spleen, liver, lung, brain, large intestine, kidney, adrenal gland, and
eye) for virus titer determination, histopathology and immunohistochemistry (IHC) analysis, as
described below. Whole blood was collected for clinical chemistry analysis, and serum was
assayed for viral load and kinetic alanine aminotransferase (ALT) levels.
Virus titer determination
Virus titers were assayed using an infectious cell culture assay. Tissue samples were
homogenized in a fixed volume of MEM and the homogenate and serum were serially diluted
and added to quadruplicate wells of Vero cell monolayers in 96-well microplates. The viral
cytopathic effect (CPE) was determined 3-4 days post-plating, and the 50% endpoints were
calculated as described [92]. The lower limit of detection for serum samples was 1.75 log 10
CCID 50 /ml and the lower limit of detection for tissues was generally in the range of 2-3 log 10
CCID 50 /g.
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Kinetic serum alanine aminotransferase (ALT) determinations
Detection of ALT in serum is an indirect method for evaluating liver dysfunction. Serum
ALT concentrations were measured using the ALT (SGPT) Reagent Set purchased from Pointe
Scientific, Inc. (Lincoln Park, MI) per the manufacturer’s recommendations. The reagent
volumes were adjusted for analysis on 96-well microplates.
Histopathology
Tissue samples of the pancreas, spleen, liver, lung, kidney, adrenal gland, large intestine,
brain and eye were obtained at prescribed necropsy times and preserved for 3 weeks in 10%
neutral buffered formalin. The samples were subsequently sent to the Utah Veterinary
Diagnostic Laboratory (Logan, UT) for blinded histopathology examination and analysis by a
board certified veterinary pathologist.
Immunohistochemical staining
Based on viral burden in the tissues and histopathology review, replicate tissue sections
from a representative animal per sacrifice group were selected for immunohistochemical (IHC)
staining. The sections were deparaffinized and rehydrated by standard histological procedures
with xylene-ethanol, descending grades of alcohol, and distilled water. Briefly, sections were
immersed in DakoCytomation Target Retrieval Solution (Dako Corp., Carpinteria, CA), boiled at
125°C for 4 minutes in a decloaking chamber (Biocare Medical, Concord, CA), permeabilized with
0.5% X-100 in PBS, and exposed to a peroxide block using 3% hydrogen peroxide. Slides were
then incubated in 10% normal goat serum (NGS) and 0.2% Triton X-100 in PBS for 1 hour, and
subsequently incubated with a mouse anti-RVFV Ab (1:1000; RVF MP-12 mouse hyperimmune
ascites fluid provided by Dr. Robert Tesh, World Reference Center for Emerging Viruses and
Arboviruses, University of Texas Medical Branch, Galveston, TX) for 24 hours at room
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temperature. Secondary antibody using goat anti-mouse horseradish peroxidase (1:200; SigmaAldrich, St. Louis, MO) was applied to the slides for 1 hour, then incubated for 15 minutes using
Immpact™ NovaRed substrate (Vector Laboratories, Burlingame, CA), and counterstained with
hematoxylin QS nuclear counterstain (Vector Laboratories). Lastly, sections were dehydrated in
ascending grades of alcohol, passed in xylene and permanently mounted with non-aqueous
mounting medium VectaMount (Vector Laboratories). The stained slides were sent to the Utah
Veterinary Diagnostic Laboratory for IHC/histopathology examination and analysis by a board
certified veterinary pathologist.
Results
Susceptibility of hamsters to RVFV
The initial titration of the ZH501 strain of RVFV in golden Syrian hamsters revealed a
rapid disease progression which was predominately lethal. Clinical signs of illness including
lethargy, ruffled fur, and hunched posture were observed in many of the animals by day 2 postinfection (p.i.). The virus was uniformly lethal within 2-3 days following s.c. route inoculation at
doses of 10 PFU or greater (Figure 1A). Only animals that received the lowest infectious dose of
approximately 1 PFU (based on plaque titration in Vero 76 cells) survived the challenge.
Although none of these animals succumbed to infection, the slow weight gain at the onset of
the experiment, followed by the marked increase in weight beginning day 6 p.i. suggests that
the animals were likely exhibiting some degree of illness (Figure 1B).
Characterization of RVFV disease progression
Based on the titration experiment demonstrating high susceptibility of hamsters to s.c.
RVFV infection, we next challenged animals with either 10 or 1 PFU of RVFV to assess the natural
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Figure 1. RVFV challenge of golden Syrian hamsters is rapidly lethal. Groups of 5-6 hamsters
were infected s.c. with 0.2 ml of viral inoculum containing the indicated PFU of RVFV. Mortality
was monitored over a 15-day period. A) Percent survival and B) mean % change in weight of
surviving animals relative to respective day 0 weights measured every 3rd day are shown.
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history of disease. Subsets of animals were sacrificed on day’s 1 - 4 p.i., to examine the
development of viremia, tissue titers, ALT, and histopathology in a temporal fashion. Because
all animals receiving 10 PFU in the titration study succumbed by day 3 p.i., this portion of the
study was designed to have only a day 1 and 2 sacrifice. For the animals challenged with 1 PFU,
several animals scheduled for sacrifice on day 3 (3 of 6 hamsters) and 4 (2 of 6 hamsters)
succumbed prior to the time of sacrifice. The threshold for lethality appears to be very close to
1 PFU, and thus the lack of mortality with the 1 PFU challenge in the titration study is likely due
to experimental variability in the preparation of the challenge stock.
In the 10 PFU challenge group, serum ALT was not elevated until day 2 p.i.,
demonstrated by a high level in one hamster, and slightly elevated concentrations in two others
(Figure 2A). In one animal, low level viremia and liver virus was detected as early as day 1 p.i.
(Figure 2B, C). In the day 2 p.i. cohort of animals two hamsters had virus in all tissues examined,
with low-level or undetectable virus burden in the other two animals (Figure 2B-K).
When the RVFV challenge dose was reduced to 1 PFU, ALT concentration was
dramatically elevated on day 3 (>2300 IU/L) in the only surviving hamster which also had
significant liver virus titers (Figure 3A and C, half-filled triangle). Despite substantial viral loads
in the livers of 3 of the 4 animals in the day 4 group, ALT levels were not significantly elevated.
Little to no virus was detected in the serum 24 h after challenge and only one of four hamsters
had viremia in the 48 h cohort (Figure 3B). By day 3 p.i., 2 of 3 surviving animals had measurable
virus, and on day 4 p.i., 3 of 4 hamsters had remarkable viremia. In general, the day 3 and day 4
animals with high viremias had substantial viral loads in all tissues examined; the highest levels
of virus were found in the liver, spleen, lung, kidney and adrenal gland (between 8.5-9.4 log 10
CCID 50 /g), and significant amounts were detected in the brain, pancreas, large intestine and the
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Figure 2. Temporal analysis of ALT levels and virus titers in hamsters challenged s.c. with 10
PFU of RVFV. Groups of 4 animals were sacrificed on the specified days post-infection for
analysis of A) serum ALT concentration, and B) serum, C) liver, D) spleen, E) brain, F) lung, G)
kidney, H) adrenal gland, I) pancreas, J) large intestine, and K) eye virus titers. Unique symbols
represent values for the same animal across all parameters assessed and the gray dotted lines
represents the limits of detection for each tissue or serum. DPI, day post-infection.
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Figure 3. Temporal analysis of ALT levels and virus titers in hamsters challenged with 1 PFU of
RVFV. Groups of 3-4 animals were sacrificed on the specified days post-infection for analysis of
A) serum ALT concentration, and B) serum, C) liver, D) spleen, E) brain, F) lung, G) kidney, H)
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the grey dotted lines. Unique symbols represent values for the same animal across all
parameters assessed. DPI, day post-infection
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eye (between 5.9-7.9 log 10 CCID 50 /g) (Figure 3C-K). Due to the expiration of several hamsters
prior to their designated time of sacrifice, it is important to note that data from these animals
with the most severe disease are not represented in the day 3 and 4 data.
Histopathology and IHC analysis
Histopathology and subsequent IHC analysis was performed on all collected tissues, as
described above. Histologic examination of tissues from animals challenged with10 or 1 PFU
identified the liver as the primary target organ of infection. Overall, the main histologic lesion of
the liver was randomly distributed multifocal acute hepatocellular necrosis with frequent
eosinophilic intranuclear inclusions (Cowdry type A) bodies in hepatocytes surrounding the
areas of necrosis during the acute infection (Figure 4D), which become apparent by day 2 and 3
p.i. for the 10 and 1 PFU challenged animals, respectively.
In general, the spleens of hamsters from both 1 and 10 PFU challenge groups exhibited a
mild increase in lymphocyte area, and cellularity of the periarteriolar lymphoid sheath and
lymphoid follicle. Erythrocyte depletion of the splenic red pulp, possibly due to splenic
contraction, was detected in 2 of 4 animals in the 10 PFU group at day 1 p.i, with one animal
also having white pulp (lymphoid) depletion (Figure 4E). In the day 2 p.i. 10 PFU sacrifice group,
3 of 4 animals began to exhibit multifocal hepatocellular necrosis; one animal also had
discernable erythroid and lymphoid depletion (Figure 4F). Comparatively, erythroid or lymphoid
depletion was not observed in the 1 PFU challenge group until day 3 p.i. in 1 of the 3 surviving
animals (Figure 4F). Additionally, a significant amount of cell debris in the red pulp was
observed, suggesting necrosis or apoptosis of lymphocytes and/or other circulating cells
migrating through the splenic parenchyma. Of the hamsters sacrificed on day 4 p.i. only one
animal had detectable white pulp depletion (data not shown). Little to no significant
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microscopic lesions was observed in pancreas, lung, brain, large intestine, kidney, adrenal gland,
or eye tissues.
Successive IHC staining and analysis of the collected tissues generally demonstrated
increased immunoreactivity in the livers with the most severe lesions. No immunoreactivity was
observed in any of the animals challenged with 10 PFU at day 1 p.i., but by day 2 p.i.
approximately 30-40% of hepatocytes examined showed diffuse to multifocal and mild to strong
cytoplasmic staining for RVFV antigen (Figure 5B); positive hepatocytes are in small groups or
randomly distributed individual hepatocytes. The 1 PFU challenge group did not display any
immunoreactivity until day 3 p.i., when IHC staining revealed most hepatocytes (approximately
90%) in the liver sections having strong, diffuse, cytoplasmic immunoreactivity for RVFV antigen
(Figure 5C). Occasional multifocal RVFV positive cells were present in the sinusoids and were
interpreted as likely infected Kupffer cells (data not shown). On day 4 p.i. approximately 40-50%
of hepatocytes exhibited a multifocal to diffuse, and mild to strong, cytoplasmic
immunoreactivity for RVFV antigen (Figure 5D); positive hepatocytes are in larger areas/groups
of hepatocytes. The hepatocytes surrounding the areas of hepatocellular necrosis were positive
for RVFV, but only rare cell debris was positive for viral antigen in the areas of necrosis (Figure
5D). Inclusion bodies in the nuclei of hepatocytes, endothelial cell lining blood vessels and
sinusoids, and biliary cells were not immunoreactive. As observed with the 10 PFU animals, no
staining for RVFV antigen was observed in the spleen, brain, kidneys, lung, pancreas, adrenal
gland, intestine, blood vessels, or eye in the hamsters challenged with 1 PFU.
Discussion
Although previous studies have examined the susceptibility of hamsters to lethal RVFV
infection [37,44,45,89-91], a more detailed description of the natural history is lacking. Here,
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Figure 4. Histological findings in livers and spleens from RVFV-infected hamsters. A) Hamster
liver section from sham-infected control animal showing normal liver histology, 400X, bar = 50
µm. B) Hamster spleen from sham-infected control showing normal red pulp, 200X, bar = 100
µm and C) white pulp, 400X, bar = 50 µm. D) 1 PFU, day 3 p.i. hamster liver (Figure 3, half-filled
triangle) showing acute hepatocellular necrosis and eosinophilic nuclear inclusions (arrows) in
hepatocytes surrounding the area of necrosis, 600X, bar = 30 µm. E) 10 PFU, day 2 p.i. hamster
spleen (Figure 2, open triangle) displaying diffuse erythroid depletion of the red pulp and
lymphoid depletion of the white pulp, 200X, bar = 100 µm. F) 1 PFU, day 3 p.i. hamster spleen
(Figure 3, half-filled triangle) displaying diffuse lymphoid depletion of the white pulp.
Heterochromatic cell fragments, indicative of apoptotic bodies and tingible body macrophages
with cytoplasmic phagocytized apoptotic debris are scattered in the periarteriolar lymphoid
sheath. 400X, bar = 50 µm. Hematoxylin and Eosin stain.
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Figure 5. Immunohistochemistry analysis of liver tissues from RVFV-infected hamsters
demonstrates presence of viral antigen. A) Hamster liver section from sham-infected control
animal, 400X, bar = 50 µm. B) 10 PFU, day 2 p.i. hamster liver (Figure 2, open circle) with 3040% of hepatocytes exhibiting immunoreactivity for RVFV antigen, 20X, bar = 100 µm. C) 1 PFU,
day 3 p.i. hamster liver (Figure 3, half-filled triangle) with hepatocytes showing strong diffuse
cytoplasmic immunoreactivity for RVFV antigen, 400X, bar= 50µm. D) 1 PFU, day 4 p.i. hamster
liver (Figure 3, open upside-down triangle) with hepatocytes positive for RVFV antigen, 400X,
bar = 50 µm. NovaRed stain with hematoxylin QS counterstain.

26
Table 1. Comparison of RVFV animal models to the Syrian hamster model.

a

Strain dependent
Elevated body temperature prior to death
c
Ribavirin-treated animals
d
Aerosol challenge
ND, not determined; NEI, not enough information. NEI.
b
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we have characterized a model of s.c. RVFV infection in hamsters based on challenge with the
ZH501 strain of the virus and discuss our findings in terms of other rodent RVFV models and
severe cases of disease in humans. Consistent with earlier studies reporting a high degree of
susceptibility, hamsters succumbed to a 10 PFU challenge with the ZH501 strain of RVFV within
2 to 3 days. By comparison, C57BL/6J mice challenged with 100× more PFU of the same virus
stock succumbed in 3 to 6 days [39], underscoring the heightened sensitivity of hamsters to
acute RVFV-induced disease.
As described by Smith and colleagues [13], we found that a wide variety of tissues
supported RVFV infection in hamsters. Moreover, previous hamster studies utilizing RVFV
describe viremia and elevated viral loads in liver, brain, and spleen tissues similar to our findings
[37,45,91]. Based on our viral titer, serum ALT, histopathology, and IHC data, the liver was
clearly the primary target for RVFV infection. The severe hepatocellular necrosis seen early
during infection and the intense IHC staining of affected hepatocytes suggests that the hamsters
were likely succumbing from fulminant hepatitis. This is in contrast to the age-dependent gerbil
RVFV infection model where liver involvement is minimal and encephalitis is believed to be the
cause of death [47]. Marked elevation of serum ALT levels indicative of liver dysfunction was
observed in several hamsters in the 10 PFU challenge group that had substantial liver viral titers.
In contrast, despite considerably high viral loads on day 4 in the livers of most of the hamsters
challenged with 1 PFU, the ALT levels were not elevated. We suspect that delayed seeding of
the liver may have resulted in slower replication of RVFV in the low-dose (1 PFU) challenge
group, thereby affecting the kinetics of hepatocellular damage and subsequent release of ALT
into the circulation. In mouse RVFV infection models, substantial liver viral titers have been
observed as early as day 2 p.i., yet increases in serum ALT levels lag behind by approximately 1
day [13,39,41].
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Although infectious RVFV was present in many tissues, histopathology was restricted
primarily to the liver and, to a lesser extent, the spleen. The mild increase in lymphocyte area
and cellularity of the periarteriolar lymphoid sheath and lymphoid follicle of the spleen, in
conjunction with the observed red and white pulp depletion, is similar to the pathology
documented in the PTV hamster infection model wherein splenic necrosis involving both the red
pulp and the lymphoid zone [76]. In contrast, PTV-infected C57BL/6 mice present with lesions
that are more prominent in the white pulp [77]. RVFV infection in BALB/c mice displayed
depletion of red pulp and lymphocyte apoptosis [13]. Although apoptotic bodies were visually
identified, we did not perform a TUNEL assay or electron microscopy to confirm cellular
apoptosis of the splenic white pulp.
The lack of RVFV antigen staining in tissues which contain high infectious viral loads and
limited cellular damage, as observed in the spleen, could be due to a delay in the accumulation
of detectable levels of antigen which may have reduced immunoreactivity due to masking by
prolonged exposure to the formalin preservative. In the study by Smith et al., infectious RVFV
was detected in the brain as early as day 3 p.i. yet antigen was not detected until day 6 p.i. and
histological changes in the brain were not pronounced until day 8 p.i. [13]. A different study
investigating chemotactic and inflammatory responses in mice reported that despite moderate
amounts of necrotic debris observed in the spleen, viral antigen was not detectable in 20% of
RVFV infected mice, and only very low level staining was observed in a small percentage of cells
in the remaining 80% of the animals [41]. Additionally, in the related hamster PTV infection
model, despite marked splenic necrosis, viral antigen was not detected [76].
Due to the inherent challenges of collecting samples from lethal cases of RVFV infection
in remote regions of Africa and neighboring regions where the virus is endemic and medical
infrastructure is often lacking, detailed description of RVF is limited. The development of non-
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human primates (NHP) models of RVFV infection has facilitated investigations into the
pathogenesis of the disease and the evaluation of potential antiviral therapies [3]. During
severe infections in rhesus macaques, hemolytic anemia, extensive liver necrosis and possible
disseminated intravascular coagulation (DIC) have been reported [49,50,93]. Despite limited
histologic and IHC data, viremia, elevated serum ALT levels, and increased viral titers in the livers
and spleens of fatally infected monkeys are consistent with our findings in RVFV-infected
hamsters. Although both species develop significant lesions in the liver following RVFV
challenge, the macaques exhibit a coagulative necrosis with cellular infiltrates not specifically
observed in the hamster infection model [94]. Spleens from RVFV-infected rhesus macaque
contained deposits of eosinophilic fibrin-like material in the red pulp of the spleen and a mild
depletion of lymphocytes in the white pulp, similar to human infection, and our findings in
hamsters infected with RVFV [93].
Although NHP models are considered the gold-standard when modeling RVF, they are
cost-prohibitive and require special handling facilities. Thus, rodent models are better suited for
initial stages of antiviral drug and vaccine development. Unlike NHP models, challenge of
commonly used rodent species produces peracute disease and uniform lethality. The high
mortality is favorable for antiviral and vaccine efficacy studies, but the often sublethal infection
in NHPs is more representative of human infection wherein only a small percentage of those
exposed progress to severe disease [10,95-97]. Table 1 provides a comparison of the principal
RVFV infection animal models in terms of general aspects one may want to consider to assist in
selecting the most appropriate model for their research needs. These are only generalized
guidelines as many factors such as the route of infection, dose and strain of challenge virus, and
the age and strain of the animal species can affect the outcome of RVFV infection and
associated disease.
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In summary, RVFV infection of hamsters most closely resembles the disease observed in
mice, but with a more accelerated progression. Although rapid lethality makes for an
abbreviated therapeutic window and translation to the human condition difficult, the uniform
lethality via low-dose inoculation with an acute, fulminant hepatic disease makes the hamster
RVFV infection model a cost-effective system for evaluating experimental vaccines and antivirals
to demonstrate initial proof-of-concept. More specifically, the hamster model is most useful for
the evaluation of host-targeted interventions that are not active in the mouse, but do crossreact with the orthologous target in hamsters [88]. In addition, the ability to reliably produce a
delayed neurologic disease when treating RVFV infection with ribavirin may prove useful for
future studies investigating the role of ribavirin in late-onset neuroinvasion and associated
encephalitis and the evaluation of potential neuroprotective countermeasures [84]. Infection by
low volume intranasal or aerosol exposure should be evaluated to determine whether
neurologic disease is favored under such exposure conditions, as has been demonstrated in
mice [98]. This challenge route is highly relevant in terms of biodefense, as it would mimic
respiratory route exposure that could occur through intentional release, and would likely
produce a slower-progressing disease model.
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CHAPTER 3
FAVIPIRAVIR (T-705) EVALUATION STUDIES
Introduction
Favipiravir (T-705; 6-flouro-3-hydroxy-2-pyrazinecarboxamine) is a promising pyrazine
derivative that has demonstrated potent antiviral activity against multiple RNA viruses [70].
Intracellular host enzymes act upon T-705 converting it to its active form, T-705-4-ribofuranosyl5-triphosphate (T-705RTP) [71]. T-705RTP functions as a purine nucleotide analog that
selectively inhibits RNA-dependent RNA polymerase (RdRp) of the influenza virus [99-101]. T705 has demonstrated a 150-fold weaker inhibition of inosine monophosphate dehydrogenase
than ribavirin, and unlike ribavirin it does not interfere with DNA or RNA synthesis. The
specificity of T-705 likely contributes to its low toxicity. Recently, the compound has received
approval as an influenza inhibitor in Japan (”AVIGAN®Tablet 200 mg”) and is presently in clinical
development in the United States (Phase 3 clinical trial).
T-705 has demonstrated robust activity against the MP-12 vaccine strain of RVFV in cell
culture [40,74]. Additionally, the antiviral activity of T-705 in vitro against several other related
bunyaviruses (several hantaviruses, La Crosse virus, and Punta Toro and sandfly fever
phleboviruses) have been reported [40,72,73]. Punta Toro virus (PTV), a more accessible and
less biohazardous agent (biosafety level 2; BSL-2) belonging to the same genus as RVFV, has
been used to model severe RVFV infection in different animal models [75-77]. Consequently,
initial studies evaluated the efficacy of T-705 in PTV infection models [40,74]. Based on
promising results demonstrating T-705 inhibition of PTV infection in established rodent models
and in vitro activity of the compound against the MP-12 strain of RVFV, we next investigated the
efficacy of T-705 against our newly established s.c. ZH501 RVFV infection model in golden Syrian
hamsters.
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Materials and Methods
Virus and cells
RVFV, strain ZH501, was obtained from Dr. Stuart Nichol (CDC, Atlanta, GA). The virus
stock (1 passage in BSRT7 cells and 3 passages in Vero E6 cells) was derived from a clarified cell
culture lysate and titrated to be at a concentration of 1.1 × 108 plaque-forming units (PFU)/ml.
The African green monkey kidney cell line, Vero 76, was purchased from the American Type
Culture Collection (ATCC) (Manassas, VA) and maintained in minimal essential medium (MEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Thermo Fisher Scientific
HyClone, Logan, UT). For in vitro antiviral assays, the serum was reduced to 2% FBS and
gentamicin (Sigma-Aldrich, St. Louis, MO) was added to the medium to a final concentration of
50 µg/ml.
Compounds
T-705 was provided by the Toyama Chemical Company, Ltd. (Toyama, Japan). Ribavirin
was from ICN Pharmaceuticals, Inc. (Costa Mesa, CA). For in vivo studies, both compounds were
suspended in 0.4% carboxymethylcellulose (CMC) (Sigma-Aldrich, St. Louis, MO) prior to
administration. For cell culture testing, T-705 and ribavirin were dissolved in MEM containing
50 µg/mL gentamicin.
In vitro antiviral testing
RVFV was titrated on Vero 76 cells (~80% confluent) plated in 96-well microplates in
culture medium containing 2% FBS to a cell culture infectious dose (CCID) that produced
maximal cytopathic effects (CPE) in 3 days. Half-log dilutions of T-705 and ribavirin were added
in triplicate to test wells at the time of infection with the highest test compound concentration
of 1000 µM. For toxicity determinations, drugs were added in the prior to virus challenge.
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Plates were incubated at 37°C and 5% CO 2 until virus-infected control wells were observed to
have > 90% CPE (day 3). The neutral red (NR) assay was performed using a modified method of
Cavanaugh et al. [102] as described [103]. Briefly, the supernatants were removed for virus
yield reduction (VYR) assays and infected cells and controls were subsequently stained with
0.011% NR solution for 2 h at 37°C and 5% CO 2 . After incubation, the NR solution was removed,
the wells were rinsed with phosphate-buffered saline (PBS), and the incorporated dye extracted
using ethanol buffered with Sorenson’s citrate. The plates were read at 405 (primary) and 540
(reference) nanometer wavelengths using a Opsys MRTM microplate reader (Dynex Technologies,
Chantilly, VA) to quantitate the extracted NR. The absorbance values were expressed as
percentages of untreated, uninfected controls, which took up maximal dye. The values obtained
were converted to percentages of untreated, uninfected controls. The 50% cell cytotoxic dose
(CC 50 ) and 50% effective concentration (EC 50 ), representing the concentration at which 50% of
the monolayers would show compound cytotoxicity or viral CPE, respectively, were estimated by
regression analysis. The selectivity index (SI) was calculated using the formula: SI = CC 50 /EC 50 .
For the VYR assays, viral titers were determined by endpoint dilution [92]. The VYR data are
presented as the concentration of drug that reduced the virus yield by 1 log 10 unit (EC 90 ) based
on linear regression analysis, with SI values determined as the CC 50 /EC 90 .
Animals and ethics regulation
Female 90-115 g golden Syrian hamsters (The Charles River Laboratory, Willimantic, CT)
were quarantined for 7 days prior to challenge and fed standard Harlan lab block and tap water
ad libitum. All animal procedures complied with USDA guidelines and were conducted at the
AAALAC-accredited Laboratory Animal Research Center at Utah State University under protocol
1502, approved by the Utah State University Animal Care and Use Committee.
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T-705 Dosing optimization for RVFV treatment
To determine the most appropriate dose for subsequent efficacy studies, hamsters
(n=15/group) were challenged by subcutaneous (s.c.) injection (ventral, right side of the
abdomen) with a 0.1 ml inoculum containing 30 PFU of RVFV and varying doses of oral (p.o.) T705 were evaluated for efficacy. Treatments, including 75 mg/kg/day of ribavirin (positive
control) or 0.4% CMC placebo, were initiated 1 h post-infection (hpi) and administered twice
daily for 10 days. Five animals from each treatment group were designated for sacrifice on day
3 of infection for analysis of serum, liver and spleen viral titers. The remaining animals were
observed 28 days for morbidity and mortality. Sham-infected normal animals were included as
baseline controls for morbidity and mortality (n=3), and virus titer assays (n=3). Serum, brain,
liver and spleen samples were collected from two moribund animals with late-onset encephalitic
disease for viral titer determination and histopathology.
Extended post RVFV exposure T-705 efficacy study
Since hamsters begin to succumb to s.c. RVFV challenge within 48 h, we performed a
follow-up experiment wherein treatments with the effective dose of T-705 were initiated 1, 6,
and 24 hpi. Hamsters (n=14 each for treatment and placebo groups) challenged with 30 PFU of
RVFV were dosed orally, twice daily for 14 days, with T-705 (200 mg/kg/day), ribavirin (75
mg/kg/day), or placebo starting 1, 6 or 24 hpi. Four animals from each treatment group were
sacrificed on day 2 of infection for analysis of viral titers. The remaining animals were observed
28 days for morbidity and mortality. Sham-infected normal animals were included as baseline
controls for survival (n=3) and virus titers (n=3). As done in the first study, serum, brain, liver
and spleen samples were collected from several moribund animals with late-onset encephalitic
disease for viral titer determination and histopathology.
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Combined post-exposure treatment of RVFV Infection with T-705 and ribavirin
The combined antiviral effects of T-705 and ribavirin were evaluated based on
differences in their protective effects observed in the monotherapy studies. Hamsters (n=14 for
treatment groups, n=24 for placebo group) were challenged s.c. with 30 PFU of RVFV and T-705,
ribavirin and placebo were dosed separately or in combination, as described in Table 1, starting
24 hpi. Four animals from each treatment group were sacrificed on day 2 of infection for
analysis of viral titers. The remaining animals were observed 28 days for morbidity and
mortality. Sham-infected controls were included for comparison.
Serum, liver, spleen and brain virus titers
Virus titers were assayed using an infectious cell culture assay as previously described
[39]. Briefly, a specific volume of tissue homogenate or serum was serially diluted and added to
triplicate wells of Vero 76 cell monolayers in 96-well microtiter plates. The viral CPE was
determined 7 days after plating and the 50% endpoints were calculated as described [92]. The
lower limits of detection for virus titers were 1.49 log 10 CCID 50 /ml serum and 1.97 log 10 CCID 50 /g
of tissue, respectively.
Histopathology
Several moribund animals were discovered between days 7-14 of the dose optimization
and post-exposure T-705 efficacy study. These animals were sacrificed for determination of
serum, liver, spleen and brain virus titers. In parallel, sections from these tissues preserved in
10% neutral buffered formalin were sent to the Utah Veterinary Diagnostic Laboratory (Logan,
UT) for blinded histopathology examination and analysis by a board certified veterinary
pathologist.
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Immunohistochemical staining
Based on viral burden in the tissues and histopathology review, replicate tissue sections
from euthanized moribund animals were processed for immunohistochemical (IHC) staining, as
described previously (Chapter 2, Materials and Methods).
Statistical analysis
The Mantel-Cox log-rank test was used for analysis of Kaplan-Meier survival curves. A
one-way analysis of variance (ANOVA) with a Newman-Keuls posttest was performed to
compare differences in viral loads. All statistical evaluations were done using Prism (GraphPad
Software, La Jolla, CA).
Results
In vitro antiviral activity of T-705 against the ZH501 strain of RVFV
The antiviral activity of T-705 was first evaluated in cell culture against the highly
virulent ZH501 strain of RVFV, and ribavirin was included as a positive control for comparison.
The CC 50 was >1000 µM for both compounds. The inhibitory activity (EC 50 ) against RVFV was 31
µM ± 18 for T-705 and 53 µM ± 22 for ribavirin by NR CPE reduction assay, with SI values of >32
and >19, respectively. The antiviral activity of T-705 was confirmed by measuring reduction in
virus yield (Figure 6) by endpoint titration of the day 3 post-infection culture supernatants. The
EC 90 of T-705 was 11 ± 27 µM and ribavirin’s was 12 ± 9 µM (SI >91 and >83, respectively),
consistent with the activity detected by the NR uptake assay. The data is consistent with the
previously observed T-705 activity against the MP-12 strain of RVFV [40,74].
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Figure 6. In vitro activity of T-705 against the ZH501 strain of RVFV. Vero 76 cell cultures were
infected with RVFV, treated with various concentrations of T-705 or ribavirin, and A) the
inhibition of viral replication was determined by endpoint titration of the culture supernatants.
B) Cytotoxicity of the compounds was determined by neutral red dye uptake to measure cell
viability in cultures of uninfected cells treated in parallel. Cytotoxicity data represent the
percent cell viability after a 3-day incubation compared to untreated controls. The data are
representative of 3 independent experiments and reflect the mean and standard deviations
from triplicate samples.
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In vivo dose optimization of T-705
We next evaluated the antiviral activity of T-705 in hamsters challenged with the ZH501
strain of RVFV. In the initial study, we assessed oral treatments of 200, 60, and 20 mg/kg/day of
T-705 administered starting 1 h post s.c. RVFV infection, dosing twice-daily for a duration of 10
days. Ribavirin, previously shown to have activity against RVFV infection [104], was included for
comparison. As shown in Figure 7A, treatment with 200 mg/kg/day T-705 was the most
efficacious regimen, protecting 80% of the challenged animals from mortality. This dose of T705 was significantly better than the ribavirin treatment (75 mg/kg/day), which only resulted in
20% survival. All the animals in the placebo and 20 mg/kg/day T-705 treatment groups
succumbed to infection by day 3. A slight protective effect was observed at a dose of 60
mg/kg/day of T-705, with 20% survival and a slight delay in the mean day of death by
approximately 1 day.
The effect of drug treatments on reducing viral titers was evaluated on day 3 in
hamsters infected and treated in parallel to those observed for mortality. Due to the peracute
lethality of the RVFV challenge in hamsters, one animal in the 60 mg/kg/day T-705 group, and all
animals in the low-dose T-705 and placebo-treated groups, expired prior to the time of sacrifice.
Viral titers in the sera, livers, and spleens of hamsters treated with 200 mg/kg/day T-705 were
significantly reduced when compared to titers in hamsters treated with 60 mg/kg/day T-705 (P <
0.05) (Figure 7B-D). Ribavirin had a similar effect on viral titers as the 200 mg/kg/day T-705
treatment. Although no virus was detected in the spleens of any RVFV-challenged hamsters
treated with ribavirin, the difference was not significant compared to the high-dose T-705 group
(Figure 7D).
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Figure 7. T-705 post-RVFV exposure treatment protects hamsters from lethal disease.
Hamsters challenged s.c. with 30 PFU of RVFV-ZH501 received the indicated doses of T-705,
ribavirin, or placebo (p.o., twice daily) beginning 1 h post-infection. A) Survival outcome and day
3 B) serum, C) liver, and D) spleen virus titers from animals infected and treated in parallel are
shown. All animals from the 20 mg/kg/day T-705 and placebo treatment groups, and one
hamster from the 60 mg/kg/day T-705 treatment group, succumbed prior to sacrifice. Unique
symbols in each treatment group represent values for the same animal in B-D. For percent
survival, **P < 0.01 and ***P < 0.001 compared to placebo; bP < 0.01 compared to animals
treated with ribavirin. For viral titers, *P < 0.05 and **P < 0.01 compared to animals treated
with 60 mg/kg/day T-705.
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In addition to the day 3 virus titer data, two animals in the ribavirin-treated group were
found in a moribund state on day 9 post-infection and sacrificed for analysis of serum, liver,
spleen, and brain virus titers, and histopathology. Remarkably, there was no virus present in the
serum, liver, or spleen; however, approximately 8.6 log 10 CCID 50 /g of tissue was present in the
brains of both animals (Figure 8A), indicating that these animals were deteriorating due to virus
replication in the brain and the associated late-onset encephalitis. This was corroborated by
histopathologic analysis which revealed neutrophilic and lymphocytic meningoencephalitis of
variable severity in the brains of both animals (Figure 8B, C).
Extended T-705 post-exposure efficacy
Because most hamsters succumb to RVFV challenge within 48 hpi, we next evaluated
the efficacy of the twice-daily 200 mg/kg/day T-705 treatments when delayed until 1, 6, and 24
h post s.c. RVFV infection. As in the initial experiment, animals receiving high-dose T-705
treatments initiated 1 hpi fared significantly better compared to the ribavirin-treated animals (P
< 0.001; 70% vs. 10% survival), which survived the acute infection but ultimately succumbed to a
late-onset neurologic disease (Figure 9A). T-705 treatment initiated at 6 hpi also demonstrated
significant protection from mortality (60% overall survival), with 3 of the 10 animals succumbing
from acute systemic infection, and a 4th from late-onset encephalitic disease. Interestingly,
ribavirin treatment delayed until 24 hpi performed similarly to treatments initiated at 1 or 6 hpi,
suggesting combination therapy with T-705 starting as late as one day after challenge may be an
effective strategy for the peracute RVFV hamster infection.
The effect of treatments on reducing viral titers on day 2 post-infection is shown in
Figure 9B-D; however, many of the placebo animals ultimately expired prior to sacrifice, thereby
limiting statistical comparison. T-705 administered at 1 hpi was very effective at limiting viral
replication as demonstrated by low or undetectable serum, liver, and spleen viral titers. Most of

41
the animals in the 6 hpi T-705 group had titers considerably higher than the 1 hpi T-705-treated
animals, which was remarkable considering 6 out of 10 animals in the observational group
survived the challenge, and suggests even a slight reduction in titers or a delay in viral
replication may be an important factor for a favorable outcome. In general, a trend of
diminished viral titers was observed in the 6 and 24 hpi T-705-treated animals compared to the
few placebo animals that could be included in the analysis. Consistent with survival data where
ribavirin prevented death due to acute infection, ribavirin-treated animals had the lowest titers
at the 6 and 24 hpi treatment groups (Figure 9B-D).
In addition to the day 2 virus titer data, four animals from the ribavirin-treated groups
and one animal in the T-705 24 hpi group were found in a moribund state after the first week of
the study (day 7-14). These animals were sacrificed for determination of serum, liver, spleen,
and brain virus titers, and histopathology. Consistent with the previous experiment and the
transition from a systemic hemorrhagic disease to a viral encephalitis disease in mice [13], there
was no virus present in the serum or spleen and only one animal from the T-705 24 hpi group
had detectable virus in the liver (5.97 log 10 CCID 50 /g; data not shown), whereas analysis of brain
tissue revealed viral loads between 7.72-9.47 log 10 CCID 50 /g in all moribund animals (Figure
10A).
Similar to the observations of the previous study, histopathologic analysis of tissues
from the moribund animals suggests that the deterioration of the animals was likely due to a
neutrophilic and lymphocytic meningoencephalitis of variable severity (Figure 10B-E). Minimal
to no lesions of hepatitis were present in most animals (data not shown). Collectively, the
histopathology data is consistent with the notion that death of animals beyond day 7 is primarily
due to RVFV replication in the brain. Central nervous system (CNS) infection and associated
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B

C

Figure 8. Sub-acute central nervous system RVFV infection in ribavirin-treated animals that
survive the acute disease. Hamsters were treated as described in Figure 7. Two animals in the
ribavirin-treated group were found to be moribund on day 9 post-infection and were sacrificed
for analysis of serum, liver, spleen, and brain virus titers, and histopathology. A) Analysis of viral
titers in moribund RVFV-infected hamsters treated with ribavirin. Histopathologic findings in
the cerebrum display B) multifocal neuronal necrosis and neuronophagia and C) neuropil
necrosis. H&E staining, 400X, bars = 20 µm.
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Figure 9. T-705 intervention is effective out to 6 h post-RVFV exposure. Hamsters were
treated with T-705 (200 mg/kg/day), ribavirin (75 mg/kg/day), or placebo, twice-daily p.o. for 14
days beginning 1, 6 or 24 h post-infection (hpi). A) Percent survival and day 2 B) serum, C) liver,
and D) spleen virus titers are shown. Five animals from varying placebo groups and one animal
from the T-705 24 hpi group succumbed prior to sacrifice. Unique symbols in each treatment
group represent values for the same animal in B-D. *P < 0.05 and ***P < 0.001 compared to
respective placebo groups; bP < 0.01 and cP < 0.001 compared to animals treated with ribavirin.
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disease was likely the cause of death in the 29 ribavirin-treated animals that succumbed to the
RVFV challenge.
T-705 and ribavirin combination treatment of RVFV infection
Although ribavirin effectively protected hamsters from the acute disease when initiated
24 hpi, most succumbed from late-developing brain infection and disease. Considering
ribavirin’s capacity to provide protection against lethality due to acute disease even when
treatment is delayed until 24 hpi, and the encouraging efficacy of T-705 when given early during
infection, we evaluated the two compounds as a combination therapy in an effort to provide
optimal protection in hamsters challenged with RVFV. Several T-705 and ribavirin regimens
(Table 2) were tested with treatment initiated at 24 hpi. Because ribavirin treatment courses
commonly employ a “loading dose” strategy [68,105], we designed the combination study with
this consideration in mind. In addition, a lower dose of ribavirin was also evaluated to address
concerns with toxicity [106], since effectively reducing the dose requirement would greatly
benefit patients.
As shown in Figure 11A, all combination treatments resulted in significant benefit
compared to either drug alone. Treatments for G2 and G3 were the most effective, providing a
40% protection, whereas the treatment for G1 resulted in only 10% survival. Although G1
received the highest effective concentration of both compounds, the G2 and G3 treatments
(Table 2) appeared to be superior in that there were ultimately more survivors. Notably, the
combination treatment groups were the only ones to have any survivors, as all but one animal
(which ultimately succumbed on day 23) from the individual drug treatment groups expired by
day 11. Overall, the G2 and G3 combination therapy groups trended towards hamsters surviving
longer than the ribavirin 40 mg/kg/day monotherapy.
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Figure 10. Analysis of brain viral titers in moribund RVFV-infected hamsters treated with T705 or ribavirin. Hamsters were treated as described in Figure 7. Five animals were discovered
moribund and euthanized on the indicated day (d) post-infection for analysis of virus titers and
histopathology. A) Brain viral titers in moribund RVFV-infected hamsters treated with T-705
(blue symbol) or ribavirin (red symbols). Histopathologic analysis of cerebrums displayed B)
perivascular mixed inflammatory cell infiltration, C) neutrophilic choroiditis and ventriculitis, D)
neutrophilic meningitis and E) neuropil vasculitis and hemorrhage. H&E staining, 400X, bars =
50 µm.
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The effect of the drug combinations on reducing viral titers on day 2 post-infection is
shown in Figure 11B-D. Consistent with the survival data, a general trend of diminished viral
titers was observed in all of the T-705 and ribavirin combination treatment regimens. The G2
combination treatment appeared to be the most effective at reducing viral titers in the serum,
liver and spleen when compared to the T-705 monotherapy and placebo treated groups, but it
was not significantly better than the ribavirin monotherapy. Collectively, the data indicates that
combined oral treatment of T-705 and ribavirin significantly enhance post-exposure efficacy
compared to monotherapy with either drug, but the challenge of preventing late-onset
encephalitis is still problematic when treatment is postponed until 24 h after RVFV challenge.
IHC analysis of moribund T-705- and ribavirin-treated animals
From several experiments wherein several animals receiving T-705 or ribavirin
treatment succumbed to CNS infection and associated disease in the absence of detectable
levels of infectious virus in serum or liver and spleen samples, we performed IHC analysis on the
collected tissues. Collectively, histological examination of the brains from various moribund
animals between days 7-13 p.i. showed acute multifocal random necrotizing neutrophilic and
lymphocytic meningoencephalitis with neuronal necrosis, neuronophagia and vasculitis (Figure
12A). IHC staining these same sections, revealed multifocally, neurons adjacent to areas with
neuronophagia displaying diffuse cytoplasmic immunoreactivity for RVFV antigen (Figure 12B).
Comparing the morphologic changes over the course of infection, we noted some
interesting developments in the livers and spleens from the ribavirin-treated moribund animals.
Concerning the spleen, despite the increase in lymphocyte area observed on days 3 and 4 p.i.,
the examined tissues (days 7-13) all showed granulopoiesis (extramedullary hematopoiesis) in
the spleen with an increase in circulating neutrophils in the liver sinusoids, suggesting that these
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Table 2. Post-exposure T-705 plus ribavirin combination treatment regimens.

Group

G1

G2

G3

G4

G5

G6

a

Dosage (mg/kg/day)b

Compounds

High/Low
Dosea

Day 1

Day 2

Days 3-10

T-705

H

200

200

200

Ribavirin

H (LD)

75

37.5

-

T-705

H

200

200

200

Ribavirin

L (LD)

40

20

-

T-705

L

100

100

100

Ribavirin

H (LD)

75

37.5

-

T-705

-

-

-

-

Ribavirin

L

40

40

40

T-705

H (LD)

400

200

200

Ribavirin

-

-

-

-

-

-

-

-

-

-

-

-

Placebo
Placebo

H = high, L = low, LD = loading dose.
Hamsters were treated p.o., twice per day, beginning 24 h post-infection.
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Figure 11. Combined T-705 and ribavirin therapies significantly improve survival outcome and
reduce viral burden when starting treatment 24 h post-RVFV challenge. Hamsters were
treated p.o. with T-705, ribavirin, or a combination of both compounds starting 24 h postinfection (see Table 2 for detailed description of the treatment regimens). A) Percent survival
and day 2 B) serum, C) liver, and D) spleen virus titers are shown. One animal each in the T-705
monotherapy and placebo-treated group succumbed prior to sacrifice on day 2. Unique symbols
in each treatment group represent values for the same animal for B-D. *P < 0.05, **P < 0.01,
and ***P < 0.001 compared to placebo-treated animals; aP < 0.05, bP < 0.01, cP < 0.001
compared to animals receiving T-705 monotherapy; xP < 0.05, zP < 0.001 compared to hamsters
treated only with ribavirin. H (high dose), L (low dose), LD (loading dose).
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hamsters had neutrophilia. Diffusely, there was moderate depletion of the red and white pulps,
moderate to marked lymphoid depletion of the marginal zones and lymphoid follicles, and to a
lesser extent the periarteriolar lymphoid sheaths. Examination of the liver showed minimal-tono lesions of hepatitis in half of the animals. Moreover, one of the animals displayed an
undulated liver capsular surface, increased number of bi/trinucelated hepatocytes, and the mild
biliary hyperplasia/ductular reaction with prominent oval cell in the canal of Hering suggesting
that the hepatic progenitor cell compartment was activated and that hepatic regeneration may
have occurred (data not shown).
Discussion
The present study demonstrates for the first time the antiviral activity of T-705 against
pathogenic RVFV infection. Despite similar inhibitory concentrations in the cell culture
experiments, T-705 was superior to ribavirin in terms of overall survival and preventing lateonset CNS infection in RVFV-infected hamsters. The liver is the principal target with severe
hepatic disease the likely cause of death during the acute infection with a delayed-onset
encephalitic disease developing after the first week [13,44]. Hamsters generally succumb within
2-3 days from acute disease, whereas mortality in mice occurs during the first 3-6 days [2].
While both species are highly susceptible to RVFV, neither reproduces the hemorrhagic fever or
ocular disease observed in human cases. The rapid progression of disease in hamsters presents
challenges in terms of the abbreviated therapeutic window; however, the model is very useful
for evaluating experimental therapies in the context of post-exposure intervention and to
demonstrate proof-of-concept in a robust small animal model.
It is possible that doses higher than 200 mg/kg/day of T-705 may have achieved
complete protection against lethal RVFV challenge in hamsters. The present dose of 200
mg/kg/day is equivalent to a human dose of 27 mg/kg/day based on body surface area
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conversion [107]. In the Phase 2 clinical trial evaluating T-705 as an anti-influenza drug, the high
dose arm consisted of 2400 mg on day 1 and 1600 mg on days 2-5. Assuming the average
weight of the participants was 60 kg, the dosages received were in the range of 40 and 27
respectively. Although a 400 mg/kg/day loading dose with subsequent transition to 200
mg/kg/day was evaluated in the third study, the therapeutic window for T-705 in the hamster
model appears not to extend much further than beyond 6 h. Considering the excellent
tolerability of T-705 in hamsters (LD 50 > 1500 mg/kg/day) [40], and the severity of the RVFV
infection, it may be worthwhile to explore higher daily doses administered three times per day
to obtain more consistent therapeutic levels systemically and in tissues.
One of the more remarkable findings from our studies was that although both ribavirin
and T-705 had dramatic antiviral effects on RVFV-infected hamsters, their effects on survival
were very distinct. T-705 was more effective in terms of protecting the animals from both acute
and late-onset CNS disease, but the window for successful post-exposure intervention was
limited to approximately 6 h. In contrast, ribavirin was highly effective at protecting all animals
from the rapidly overwhelming effects of the acute infection, even when delaying treatment
until 24 hpi, whereas only a slight beneficial effect could be observed with T-705 treatments.
However, almost all ribavirin-treated animals ultimately succumbed to CNS infection and
associated disease in the absence of detectable levels of virus in serum or liver and spleen
samples. This may be explained by the inability of ribavirin or its active metabolites to
effectively cross the blood-brain barrier [108]. These findings are consistent with a well
characterized mouse RVFV infection model wherein late-onset neuroinvasion and encephalitis
was described in animals succumbing during the latter part of the infection [13]. This secondary
disease observed in hamsters could serve as a model for human cases of delayed-onset
encephalitis that occur weeks to months after acute RVFV infection [2].
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Figure 12. Immunohistochemistry analysis of brain tissues from RVFV-infected hamsters
demonstrates presence of viral antigen. A) Hamster brain section from sham-infected control
animal showing normal cells, 400X, bar = 30 µm. Brain tissue from a ribavirin treated moribund
hamster at day 13 p.i. with RVFV demonstrating B) Acute neutrophilic encephalitis with necrosis
and vasculitis, 200X, bar = 100 µm, H & E stain, and C) Immunohistochemistry staining for RVFV.
Multiple neurons surrounding foci of neutrophilic inflammation and necrosis show diffuse
cytoplasmic immunoreactivity for RVFV antigen. 400X, bar = 50 µm. NovaRed stain with
hematoxylin counterstain.
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It is unclear why ribavirin is so effective at controlling viral replication and abrogating
disease when initiating treatment at an advanced time point (24 hpi) in the peracute infection.
Ribavirin may achieve higher concentrations and activation in the primary lymphatic tissues
where the virus is likely to initially replicate before seeding the blood and secondary target
organs including the liver. We can only speculate as to why T-705 is able to prevent CNS
infection, but has a narrower window for intervention. The complexities with the
biodistribution of the parent T-705 compound, the efficiency of its intracellular conversion to
the active ribofuranosyl triphosphate in various cell types and tissues, and the rate of
elimination all probably influence the observed efficacy and the shorter window for effective
intervention. T-705 is likely to specifically target the RVFV polymerase directly affecting the
virus life cycle by inhibiting viral transcription and replication, whereas ribavirin has multiple
modes of action and may prevent RVFV lethality through later acting cumulative effects from
depletion of ribonucleotide pools [67].
Our findings evaluating T-705 and ribavirin as monotherapies provided the rationale for
combining the two antivirals with the goal of integrating the beneficial aspects of each
independent treatment to extend the therapeutic window to 24 hpi. The results of the drug
combination study indicated oral treatment with T-705 and ribavirin significantly enhanced postexposure efficacy suggestive of synergy, as demonstrated by protection (up to 40% survival)
against both the acute hepatic and late-onset encephalitic disease that would otherwise result
in death in animals treated with either drug alone. Despite this success, the challenge of
preventing late-onset encephalitis when treatment is postponed until 24 h after RVFV infection
in hamsters is still largely unmet. Interestingly, our findings hint that the highest dose
combination of T-705 and ribavirin was not necessarily optimal (only 10% survival), as
treatments where the dose of one of the drugs was lowered resulted in improved (40%) survival
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outcomes. A comprehensive drug combination matrix would be needed to clearly demonstrate
possible antagonism at higher doses, as well as synergy with suboptimal dosing regimens of T705 and ribavirin.
In summary, post-RVFV exposure treatment of hamsters with T-705 within 6 hpi, or T705 + ribavirin combination therapy within 24 hpi, significantly improved survival outcome and
reduced viral loads in serum and tissues. In fatal cases of RVF, severe hemorrhagic disease
manifestations typically lead to death within 3-6 days of the onset of clinical signs of illness [2].
Because hamsters succumb to the acute phase of the infection within a day of displaying initial
clinical signs (lethargy, hunched posture, and ruffled fur), it is difficult to extrapolate to the
human disease. However, considering the rapid progression and lethality of RVFV infection and
disease modeled in hamsters, the data presented are certainly encouraging. In view of the
failure of ribavirin to prevent CNS infection in mice challenged through the upper respiratory
tract [98], future studies investigating the efficacy of T-705 against aerosol exposure in rodents
is warranted. Ultimately, investigational new drug-enabling efficacy studies in a nonhuman
primate model of RVF will be required for advancing the compound towards clinical evaluation.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS

Rift Valley fever illness typically manifests as an acute febrile and hepatic disease in
ruminant species and humans. The need to better understand the more severe manifestations
of RVF disease has led to the establishment of various animal models to study the pathogenesis
of RVFV infection [3,49]. Hamsters are increasingly being used in infectious disease research,
with the greatest increase in the field of virology [73]. Due to the increased biohazard risk
associated with RVFV, a more accessible hamster model for RVF based on challenge with the
related Punta Toro virus was established [75]. Although the hamster PTV infection model has
proved useful for reproducing certain features of severe human and animal RVFV infections
where hepatic disease is a prominent pathological feature, other features such as encephalitis
are not observed. Various murine and rat RVFV models are useful in evaluating most vaccine
and antiviral drug candidates, yet certain therapeutic platforms may have little to no activity in
these systems.
As previously reported details describing RVFV infection and disease in hamsters have
been limited, we sought to more comprehensively characterize the RVFV infection model in
golden Syrian hamsters and subsequently apply the model to evaluate the activity of the
promising broadly-active compound, favipiravir. In summary, RVFV challenge in hamsters
resulted in peracute disease and lethality within 2 to 3 days of challenge. High titer viremia and
substantial viral loads were observed in most tissues examined and histologic analysis revealed
marked hepatocellular necrosis consistent with fulminant hepatitis as the likely cause of death
of RVFV-infected hamsters. Collectively, our data shows that RVFV infection of hamsters most
closely resembles the disease observed in mice, but with a more accelerated progression.
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Although we feel that RVFV infection in hamsters provides a robust challenge model
suitable for early stage vaccine and antiviral drug efficacy studies, the model has its limitations
(e.g. abbreviated therapeutic window) and additional analyses are required to better
understand disease progression and make comparisons between hamster and the human
condition. For example, future investigations should evaluate the clinical chemistry, hematology
and coagulation. A drop in total white blood cell counts and serum glucose levels, increased ALT
and bilirubin levels and an increase in clotting time have been reported in humans and various
RVFV animal models [2,13,49,50]. We attempted to measure these and other clinical laboratory
parameters in the present study; however, logistical and technical problems within the
laboratory prevented the inclusion of such data in our analysis. It would also be of interest to
study the inflammatory response through the measurement of cytokines longitudinally during
the course of infection, using previously described methodologies for mRNA expression analysis
in hamsters [109]. This information would provide a more complete clinical evaluation of the
RVFV hamster model, as well as the host immune response to infection. Additionally, the
insertion of implantable temperature transponders to continually monitor temperature would
serve to determine whether RVFV-infected hamsters become febrile at any point during the
acute infection or during the late-onset encephalitis that was observed with drug-treated
animals that survive the systemic infection. Harvesting additional tissues such as the heart,
thymus, lymph nodes, bone marrow would provide additional details useful in comparisons with
the mouse infection model [13,14]. More importantly, analysis of reproductive organs could
provide insights into the abortion storms that are characteristic of RVF epizootics.
Studies comparing s.c. challenge to aerosol challenge in murine, rat and marmoset
systems resulted in significant differences in lethality and disease progression. Most notably,
aerosol challenge typically resulted in a slower-progressing disease with an increase in
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neuropathy [43,50,98]. Considering the rapid lethality in which RVFV overwhelms hamsters,
aerosol challenge may provide a slower-developing disease process with an expanded
therapeutic window. Considering the potential for intentional release and weaponization
[30,55,68], the development of an aerosol exposure model in hamsters is warranted for the
evaluation of promising vaccine and antiviral drug candidates. Future evaluation of the efficacy
of T-705 and ribavirin in an aerosol exposure model is needed to confirm activity of these agents
against respiratory route exposure. Studies building on our success with T-705 for the
treatment of RVFV infection are also warranted. A comprehensive drug combination matrix
should be examined to convincingly demonstrate synergy between the two compounds and
possible antagonism at higher doses. This work would be invaluable towards future
investigational new drug-enabling efficacy studies in a NHP primate model of RVFV, thereby
advancing the compound towards clinical evaluation. Moreover, as of March 24, 2014, the
Japanese Ministry of Health, Labour and Welfare approved T-705 (favipiravir) for the treatment
of influenza in people. This exciting development represents the cornerstone for off-label use
for treatment of human RVFV infection pending encouraging efficacy results in NHP models.
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